Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) Sees Large Growth in Short Interest

Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) saw a significant increase in short interest during the month of January. As of January 30th, there was short interest totaling 259,453 shares, an increase of 154.8% from the January 15th total of 101,823 shares. Based on an average daily volume of 82,534 shares, the days-to-cover ratio is currently 3.1 days. Approximately 3.9% of the shares of the company are short sold. Approximately 3.9% of the shares of the company are short sold. Based on an average daily volume of 82,534 shares, the days-to-cover ratio is currently 3.1 days.

Calidi Biotherapeutics Trading Down 7.4%

Shares of CLDI stock traded down $0.06 on Thursday, hitting $0.76. The company had a trading volume of 114,304 shares, compared to its average volume of 81,369. Calidi Biotherapeutics has a twelve month low of $0.72 and a twelve month high of $19.20. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.12 and a current ratio of 2.12. The company has a 50-day moving average price of $1.16 and a 200-day moving average price of $1.93.

Calidi Biotherapeutics (NYSEAMERICAN:CLDI) last posted its earnings results on Thursday, November 13th. The company reported ($2.21) EPS for the quarter. Sell-side analysts predict that Calidi Biotherapeutics will post -4.48 earnings per share for the current fiscal year.

Institutional Trading of Calidi Biotherapeutics

A hedge fund recently bought a new stake in Calidi Biotherapeutics stock. Warberg Asset Management LLC acquired a new position in Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 18,705 shares of the company’s stock, valued at approximately $28,000. Warberg Asset Management LLC owned 0.55% of Calidi Biotherapeutics as of its most recent filing with the Securities & Exchange Commission. 12.53% of the stock is currently owned by institutional investors.

Calidi Biotherapeutics Company Profile

Calidi Biotherapeutics is a clinical-stage biotechnology company focused on the development of targeted immunotherapies that harness the body’s innate immune system to treat cancer and infectious diseases. By delivering proprietary RNA-based immune stimulants directly into the tumor microenvironment or sites of infection, Calidi aims to trigger a robust local immune response while minimizing systemic toxicity. The company’s platform is designed to engage multiple innate immune pathways, including toll-like receptors and RIG-I-like receptors, to initiate durable antitumor and antiviral activity.

Calidi’s lead oncology programs include CB-012, an intravesical therapy in clinical development for non-muscle invasive bladder cancer, and CB-013, an intratumoral candidate targeting a range of advanced solid tumors.